Coverage evaluation of Mass Drug Administration (MDA) for lymphatic filariasis in a district of Bundelkhand Region of Uttar Pradesh
DOI:
https://doi.org/10.47203/IJCH.2022.v34i02.007Keywords:
Elephantiasis, Filarial, Mass Drug Administration, Compliance, Coverage, Effective CoverageAbstract
Introduction: Lymphatic filariasis results in severe disability that leading to severe social and economic burden at each level from individual to family, and community. This study was carried out to assess the coverage and compliance of MDA. Methods: From 300 households (1837 individuals) in both rural & urban area were covered in coverage evaluation survey by systematic selection of subunits using probability proportionate to size (PPS). Each household was visited by WHO designated team and data were collected using predesigned questionnaire. Data was compiled on MS-excel spreadsheet, frequency and percentage were calculated. Results: The overall effective coverage for all drugs was low (19.1%). The coverage was low, compliance was higher in urban as compared to rural area. Females had better coverage and compliance than males. The primary reasons for drug not offered was nobody came to offer drug, drug not swallowed was not sick, drug swallowed was useful information from drug administrator (DA). Only one female reported adverse effect. Conclusion: Increase in coverage along with decrease in coverage-compliance gap is needed to achieve filariasis elimination that warrants intense IEC activities using different platforms, development of better drug delivery strategies and strengthening monitoring system.
Downloads
References
World Health Organization (WHO). Lymphatic filariasis [Internet]. 2022 [cited 2022 June 22]. Available from: https://www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis .
NVBDCP, MoHFW GoI. Accelerated Plan for Elimination of Lymphatic Filariasis [Internet]. 2018 [cited 2022 June 19]. Available from: https://nvbdcp.gov.in/WriteReadData/l892s/103156753152 8881007.pdf .
Kumar S, Jain H, Gupta S, Niranjan A. Coverage Evaluation of Mass drug Administration of DEC for filariasis in Satna District of Madhya Pradesh: A Cross-Sectional Study. International Journal of Health and Clinical Research, 2021;4:76-80.
Bhue PK, Majhi P, Panda M. Coverage and compliance of mass drug administration for elimination of lymphatic filariasis in a district of western Odisha, India. J Evid Based Med Healthc 2021;8(24):2058-2063.
Nayak BC, Samantaray A, Krishna YB. Assessment of Mass Drug Administration activities for Lymphatic Filariasis Elimination in Vizianagaram District of Andhra Pradesh. Indian Journal of Public Health Research & Development 2020;11:164-70.
Kulkarni P, Thomas JJ, Doweraha J, Murthy MRN, Ravikumar K. Mass drug administration programme against lymphatic filariasis-an evaluation of coverage and compliance in a northern Karnataka district, India. Clinical Epidemiology and Global Health 2020;8:87-90
Gururaj NA, Ramesh, Ajaykumar G, Ravikumar K, Devendrappa BG. Coverage Evaluation Survey of Mass Drug Administration Strategy to Eliminate Lymphatic Filariasis in North Karnataka Region. Are We on Track? Ann Community Health 2020;8:1-6.
Shivalingaiah AH, Ravikumar K, Gurupadaswamy SM. Evaluation of coverage and compliance to mass drug administration for lymphatic filariasis elimination in two endemic districts of Karnataka. Int J Community Med Public Health 2019;6:3583-7.
Panika RK, Sahu R. Evaluation of coverage, compliance of mass drug administration and assessment of awareness about lymphatic filariasis in Tikamgarh district of Madhya Pradesh: a cross sectional study. Int J Community Med Public Health 2019;6:1235-40.
Haldar D, Saha SK, Ghosh T, Biswas D, Lo S, Sarkar GN. Effect of directly observed therapy (DOT) on Mass Drug Administration (MDA) coverage and status of Mass Drug Administration programme in Bankura district of West Bengal, India. IOSR Journal of Dental and Medical Sciences 2019;18(4):57-65.
Banerjee S, Bandyopadhyay K, Khan MF, Akkilagunta S, Selvaraj K, Tripathy JP, et al. Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: A mixed method study. J Family Med Prim Care 2019;8:3009-14.
Banerjee S, Ray S, Bhattacharya T, Naskar S, Mandal S, Das DK. Mass Drug Administration Coverage Evaluation Survey for Lymphatic Filariasis: An Experience from Paschim Bardhaman District, West Bengal. J Commun Dis 2018; 50:25-9.
Paul A, Samsuzzaman M, Naskar S, Ray S, Chaterjee S, Das. DKCoverage Evaluation Survey of Mass Drug Administration for LymphaticFilariasis in Purbabarddhaman District, West Bengal IOSR Journal of Dental and Medical Sciences 2018;17:10-5.
Mane VP, Bhovi RA. Evaluation of mass drug administration against lymphatic filariasis in Bidar district, Karnataka, India. Int J Community Med Public Health 2018;5:4107-11.
Hoolageri MS, Kamath R, Ravikumar K, Jagadish G, Kamath S. Evaluation of mass drug administration programme for elimination of lymphatic filariasis in Bidar district, Karnataka. Int J Community Med Public Health 2018;5:1020-3.
Gowda G, Ranganatha SCM, Srinivas R. Evaluation of Mass Drug Administration for the Elimination of Lymphatic Filariasis in Dakshina Kannada District, Karnataka. Indian J Med Sci 2018;70:19-22.
Bhatia V, Giri PP, Sahoo SS, Preeti PS, Sahu DP. Mass Drug Administration (MDA) for Elimination of Lymphatic Filariasis: Experiences from Nayagarh District of Odisha, India. Indian J Comm Health 2018;30(3):287-92.
Jadhao AR, Sahoo DP, Deshmukh JS, Raut RU, Tekam AV. Mass Drug Administration Coverage Evaluation for Elimination of Lymphatic Filariasis in Nagpur District of Maharashtra. JMSCR 2017;5:28230-6.
Haldar D, Saha SK, Dwari A, Biswas D, Lo S, Naskar S, et al. Coverage of mass drug administration and status of mass drug administration program in Bankura district of West Bengal, India. Int J Health Allied Sci 2017;6:137-42
Downloads
Published
How to Cite
License
Copyright (c) 2022 Indian Journal of Community Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.